RecruitingEarly Phase 1NCT03708627
Bimatoprost as a Treatment for Graves' Orbitopathy
The Role of Bimatoprost in Graves' Periorbitopathy
Sponsor
Johns Hopkins University
Enrollment
3 participants
Start Date
Nov 1, 2017
Study Type
INTERVENTIONAL
Conditions
Summary
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Bimatoprost Ophthalmic for people with graves ophthalmopathy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBimatoprost Ophthalmic
Bimatoprost, aka Lumigan, one drop in one eye nightly
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03708627
Related Trials
Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE National Multicenter Registry Study
NCT077163971 location
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
NCT075479301 location
Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease
NCT074007571 location
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
NCT074807201 location
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
NCT056783741 location